Alto Neuroscience (NYSE:ANRO) is a clinical‐stage biotechnology company focused on advancing precision medicine for psychiatric and neurobehavioral disorders. Founded in 2017, Alto combines advanced biomarker discovery, computational modeling and translational neuroscience to address the high unmet need in conditions such as major depressive disorder and schizophrenia. By stratifying patients based on neurobiological profiles rather than conventional symptom checklists, the company aims to improve response rates and reduce time to effective treatment.
The company’s proprietary platform integrates electroencephalography (EEG), cognitive performance measures and genetic data to identify distinct patient subtypes. Alto applies these insights to both its internal pipeline and collaborative programs, working on novel small molecules and reformulations of existing compounds. Lead programs are designed to target cognitive impairment, anhedonia and other core features of mood and psychotic disorders, with the goal of advancing precision therapies through Phase II clinical trials.
Headquartered in New York City and with a research hub in Cambridge, Massachusetts, Alto Neuroscience operates across North America and Europe. The company has formed strategic partnerships with academic research centers, patient advocacy groups and clinical consortia to validate its biomarker signatures and accelerate patient recruitment. These collaborations enable Alto to leverage real‐world data and broaden access to specialized diagnostic assessments.
Alto’s leadership team is composed of seasoned neuroscientists, clinicians and industry executives. David Di Lorenzo, MD, serves as Chief Executive Officer, bringing deep expertise in psychiatric drug development and translational research. Supported by a board of directors with backgrounds in biotechnology investment and neuropharmacology, Alto is positioned to transform the treatment landscape for neuropsychiatric conditions through data‐driven precision medicine.
